Evidence map›Paper›PMID 27404858›Full record

ArticleJournal of visualized experiments : JoVE2016

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study.

Jens O Watzlawik, Robert J Kahoud, Bharath Wootla, Meghan M Painter, Arthur E Warrington, William A Carey, Moses Rodriguez

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jens O WatzlawikDepartment of Neurology, Mayo Clinic; Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic; Center for Regenerative Medicine, Neuroregeneration, Mayo Clinic; watzlawik.jens@mayo.edu.
Robert J KahoudDepartment of Neurology, Mayo Clinic; Center for Regenerative Medicine, Neuroregeneration, Mayo Clinic; Department of Pediatric and Adolescent Medicine, Mayo Clinic.
Bharath WootlaDepartment of Neurology, Mayo Clinic; Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic; Center for Regenerative Medicine, Neuroregeneration, Mayo Clinic.
Meghan M PainterDepartment of Neurology, Mayo Clinic; Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic; Center for Regenerative Medicine, Neuroregeneration, Mayo Clinic.
Arthur E WarringtonDepartment of Neurology, Mayo Clinic; Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic; Center for Regenerative Medicine, Neuroregeneration, Mayo Clinic.
William A CareyCenter for Regenerative Medicine, Neuroregeneration, Mayo Clinic; Division of Neonatal Medicine, Mayo Clinic.
Moses RodriguezDepartment of Neurology, Mayo Clinic; Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic; Center for Regenerative Medicine, Neuroregeneration, Mayo Clinic; rodriguez.moses@mayo.edu.
Mayo Clinic in Arizona · US

Funding

Nanopore Biosensor for Kinetics of Reparative Antibodies on Plasma MembranesR01GM092993 · NIGMS · UNIVERSITY OF MINNESOTA · PI OH, SANG-HYUN · 2010 to 2013
$1.6M
Genetic Analysis of Spontaneous RemyelinationR01NS048357 · NINDS · MAYO CLINIC ROCHESTER · PI BIEBER, ALLAN JAMES · 2008 to 2011
$1.0M
Clinical Translation of a Neuron Protective Recombinant Human AntibodyR21NS073684 · NINDS · MAYO CLINIC ROCHESTER · PI RODRIGUEZ, MOSES · 2011 to 2012
$434k
NIGMS NIH HHS R01 GM092993NINDS NIH HHS R01 NS048357NINDS NIH HHS R21 NS073684
6 · The paper itself

Abstract

Antibodies of the IgM isotype are often neglected as potential therapeutics in human trials, animal models of human diseases as well as detecting agents in standard laboratory techniques. In contrast, several human IgMs demonstrated proof of efficacy in cancer models and models of CNS disorders including multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). Reasons for their lack of consideration include difficulties to express, purify and stabilize IgM antibodies, challenge to identify (non-protein) antigens, low affinity binding and fundamental knowledge gaps in carbohydrate and lipid research. This manuscript uses HIgM12 as an example to provide a detailed protocol to detect antigens by Western blotting, immunoprecipitations and immunocytochemistry. HIgM12 targets polysialic acid (PSA) attached to the neural cell adhesion molecule (NCAM). Early postnatal mouse brain tissue from wild type (WT) and NCAM knockout (KO) mice lacking the three major central nervous system (CNS) splice variants NCAM180, 140 and 120 was used to evaluate the importance of NCAM for binding to HIgM12. Further enzymatic digestion of CNS tissue and cultured CNS cells using endoneuraminidases led us to identify PSA as the specific binding epitope for HIgM12.

Indexed as

Antibody SpecificityAnimalsHumansImmunoglobulin MMiceNeural Cell Adhesion MoleculesNeuronsSignal TransductionImmunoglobulin MNeural Cell Adhesion Molecules

Identifiers

PMID27404858
PMCPMC4993309
OpenAlexW2462585186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.